Severe bleeding complication of low molecular weight heparin in a dialysis patient with deep venous thrombosis

Hao Hsi Kao, Mai Szu Wu, Ching Wei Hsu, Hui Chun Lu, Bor Yiing Jiang

Research output: Contribution to journalArticle

Abstract

Low-molecular-weight heparin (LMWH), a mixture of polysaccharide molecules, is derived from unfractionated heparin (UFH) by physical and/or chemical processes. Using subcutaneous injections of LMWH to treat patients with deep vein thrombosis has several major advantages over the use of conventional intravenous or subcutaneous UFH therapy. For instance, there is no requirement for laboratory monitoring of activated partial thromboplastin time with LMWH. However, in the report we observed a 65-year-old female with end-stage renal disease and found that she, after receiving anticoagulant treatment with Nadroparin (LMWH), developed bleeding complications. It indicates that the potential bleeding adverse effect of LMWHs should be taken into account when applied to patients with severe renal disease.

Original languageEnglish
Pages (from-to)140-145
Number of pages6
JournalJournal of Internal Medicine of Taiwan
Volume18
Issue number3
Publication statusPublished - Jun 2007
Externally publishedYes

Keywords

  • Complication
  • Hemodialysis
  • Low molecular weight heparin

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Severe bleeding complication of low molecular weight heparin in a dialysis patient with deep venous thrombosis'. Together they form a unique fingerprint.

Cite this